Paris (France), February 6, 2023 – 7:30 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced that the Extraordinary General Meeting (EGM) held today at 2 pm was able to validly deliberate with a quorum of 44.35%.

The EGM adopted all the resolutions approved by the Board of Directors.

The consolidated result of the vote by resolution and the minutes of the General Meeting will be available within the legal deadlines on the Company’s website, in the General Meetings section.

Next financial release

Full-year 2022 results: Thursday, March 30, 2023, after market close